New Drug Application Submitted to FDA for Rivaroxaban for Prevention of Stroke in Patients with Atrial Fibrillation
Links shared publicly online about this topic.
- 594total visits
New Drug Application Submitted to FDA for Rivaroxaban for Prevention of Stroke in Patients with Atrial Fibrillation
View full resource at drugs.com
Tags: Stroke, Thrombotic Event, Drug, FDA, Anti-Clotting Medication, Xarelto
Most Recently Shared on January 9, 2011 at 2:08 am By:
New Drug Application Submitted to FDA for Rivaroxaban for Prevention of Stroke in Patients with Atrial Fib... http://bit.ly/g0hDMw #drug
J&JPRD submits New Drug Application to FDA for rivaroxaban
news-medical.net — “Johnson & Johnson Pharmaceutical Research & Development, L.L.C. announced today that it has submitted a New Drug Application to the U.S. Food and Drug Administration for rivaroxaban, an investigational, oral, once-daily anticoagulant, for the prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation.” View full resource at news-medical.net
Most Recently Shared on January 6, 2011 at 1:33 pm By:
News-Medical.Net Health News and Oncology
Oncology News: J&JPRD submits New Drug Application to FDA for rivaroxaban: Johnson & Johnson Pharmaceutical Rese... http://bit.ly/gRfAdn
NDA submitted for rivaroxaban for the treatment of non-valvular atrial fibrillation (AF) - MPR
empr.com — “Johnson & Johnson Pharmaceutical Research & Development announced that it has submitted a New Drug Application to the FDA for rivaroxaban for the prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation (AF).” View full resource at empr.com
Most Recently Shared on January 5, 2011 at 10:41 pm By:
MPR News: NDA submitted for rivaroxaban for the treatment of non-valvular atrial fibrillation (AF): Johnson & Jo... http://bit.ly/fFVHFq
NDA submitted for rivaroxaban for the treatment of non-valvular atrial fibrillation (AF) - ONA
oncologynurseadvisor.com — “Johnson & Johnson Pharmaceutical Research & Development announced that it has submitted a New Drug Application to the FDA for rivaroxaban for the prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation (AF).” View full resource at oncologynurseadvisor.com
Most Recently Shared on January 5, 2011 at 10:02 pm By:
OncologyNurseAdvisor Oncology, Nursing, Medical Education, and Medical Publisher
NDA submitted for rivaroxaban for the treatment of non-valvular atrial fibrillation (AF) http://goo.gl/fb/CjTgq
Advertisement
